Cohort Study: Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer – JAMA Oncology (link to abstract – $ for full-text)

News Release: Study finds breast cancers with low levels of HER2 protein are not a distinct subtype of the disease – Dana-Farber Cancer Institute

Commentary on Twitter

Is #HER2low a distinct BC subtype? Among >5000 pts from DFCI/Brigham, we found no relevant difference between HER2-low & HER2-0 BC. ER-exp determined disease behavior & was positively associated with HER2-low exp. Huge thanks to @stolaney1 & all coauthors!https://t.co/OfGT8LS2pH pic.twitter.com/uFxXGvOI8S

— Paolo Tarantino (@PTarantinoMD) June 23, 2022